China's antibiotic monopoly threatens Western health and military security

A new report warns that China’s dominance in antibiotic production poses a severe risk to Western health and military security. With most key ingredients sourced from China, even minor disruptions could leave Britain, the US, and Europe facing catastrophic shortages within weeks. China controls nearly all global production of antibiotic ingredients, creating a dangerous dependency. Britain relies on China for up to 90% of its supplies, while India—responsible for most US and UK antibiotics—imports 91.5% of its raw materials from Chinese factories. Just seven Chinese sites produce the core compound for penicillin, forming a critical chokepoint in the supply chain.

The top four Chinese suppliers alone account for 54% of India’s imports, meaning a single policy shift or production halt could cripple global antibiotic stocks. China’s long-term price suppression has already driven Western manufacturers out of the market, leaving only one penicillin plant operating in Austria. Experts warn that Beijing could exploit this dominance in two ways. In wartime, it could instantly cut off medical supplies to Western forces and hospitals. Even in peacetime, a ‘health blockade’—restricting exports to India—would starve the UK, Europe, and America of essential drugs. The report urges NATO and Western governments to treat antibiotic supply chains as a national security priority. It calls for urgent investment in manufacturing outside China and India, alongside plans to integrate medical resilience into military readiness strategies.

Without action, the West remains exposed to a single point of failure in its drug supply. A disruption in China’s production—whether by conflict, policy, or accident—could leave hospitals and armed forces without life-saving medications in a matter of weeks. The report stresses that rebuilding domestic and allied manufacturing is now a strategic necessity.